Taysha Gene Therapies, Inc. (TSHA)
Last updated: 2026-10-20 10:02:20. Prices reflect the latest pre-market trading data. Stock price data is sourced from Massive.
Summary
Taysha Gene Therapies, Inc. (TSHA) operates in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector and is listed on NASDAQ. The stock is currently priced at $3.86, with a market capitalization of $1.18B and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $3.46 to $7.30. This page covers its latest market performance, valuation, price trends and company information.
Key Market Data
$1.18B | |
$3.94 | |
$33.35 | |
$0.50 | |
$3.94 | |
1.09K | |
3.40M | |
-- | |
$7.30 | |
$3.46 | |
-- | |
-- |
Taysha Gene Therapies, Inc. (TSHA) Pre-Market Stock Price
Taysha Gene Therapies, Inc. (TSHA) is trading at $3.86 in pre-market trading as of 2026-10-20 09:25:00, down 2.13% ($0.08) from the previous close of $3.94
Pre-market trading shows how investors are pricing TSHA before the regular session opens. The current pre-market price is below the previous close, indicating cautious early trading sentiment.
Taysha Gene Therapies, Inc. (TSHA) 7-Day Stock Price Change
Over the past seven days, Taysha Gene Therapies, Inc. (TSHA) moved from $4.49 to $3.86, representing a decline of 14.12% ($0.63).
The stock traded between $3.46 and $4.57 during the period. The latest price is near the middle of the 7-day range, indicating strong downward.
The average daily volume was 4.76 million shares, up versus the previous seven-day period, indicating higher trading activity.
TSHA 52-Week Price Position
Position in Range: 10.4%
TSHA is currently trading at $3.86, placing it 10.4% of the way from its 52-week low of $3.46 to its 52-week high of $7.30. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
What is Taysha Gene Therapies, Inc. (TSHA)?
Taysha Gene Therapies Inc is a clinical-stage biotechnology company focused on advancing AAV-based gene therapies for the treatment of severe monogenic diseases of the central nervous system, or CNS. The company's clinical program TSHA-102 is in development for the treatment of Rett syndrome, a rare neurodevelopmental disorder with no approved disease-modifying therapies that address the genetic root cause of the disease. The Company views its operations and manages its business as a single operating segment, the gene therapy segment, which is the business of developing AAV-based gene therapies for the treatment of rare monogenic diseases of the central nervous system.
Taysha Gene Therapies, Inc. Information
| Industry | BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) |
| Employees | 99 |
| Exchange | NASDAQ |
| Company Website |
How to Buy Taysha Gene Therapies, Inc. (TSHA) Stock on MEXC
Eligible investors can buy real shares of Taysha Gene Therapies, Inc. (TSHA) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.
Frequently Asked Questions (FAQ)
1.What is Taysha Gene Therapies, Inc. (TSHA) stock price today?
2.Is TSHA stock going up or down today?
3.What is TSHA pre-market price?
4.What is TSHA after-hours price?
5.Is TSHA stock trading now?
6.Where does TSHA sit relative to its 52-week high and low?
7.What sector is Taysha Gene Therapies, Inc. in?
8.What is Taysha Gene Therapies, Inc.'s market capitalization and where is it listed?
9.How is TSHA valued in terms of P/E ratio and EPS?
10.Does Taysha Gene Therapies, Inc. pay a dividend?
Explore More US Stocks
Search Stocks
TSHA Stock Calculator
Estimate the value between TSHA shares and USD.
TSHA Shares to USD
1.00 TSHA shares = 3.856 USD
Calculations are estimates based on the latest available price and are for reference only.


